A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Single and Multiple Doses of KH607 Tablets in Chinese Healthy Volunteers
Latest Information Update: 08 May 2024
At a glance
- Drugs KH 607 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Chengdu Kanghong Pharmaceutical
Most Recent Events
- 08 May 2024 New trial record